Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Cancer, Cancer of Breast or Breast Carcinoma
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.

Provided treatments

  • Drug: Palbociclib
  • Drug: Letrozole
  • Biological: Trastuzumab
  • Drug: Goserelin
  • Procedure: Breast surgery
  • Procedure: Research tumor biopsy
  • Procedure: Research bone marrow (OPTIONAL)
  • Procedure: Research blood sample
  • Genetic: Research blood for germline DNA
  • Procedure: Blood for detection of circulating tumor cells
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02907918. The sponsor of the trial is Washington University School of Medicine and it is looking for 48 volunteers for the current phase.
Official trial title:
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)